Lumos Diagnostics (ASX:LDX) has reported encouraging real-world data from the use of its FebriDx point-of-care test across general practice, urgent care, and Acute Respiratory Infection hubs in the UK, showing the device can reduce unnecessary antibiotic use, improve patient satisfaction, and ease health system costs. …
Real-world evidence shows Lumos Diagnostics’ FebriDx cuts antibiotic use and delivers system savings
September 24, 2025 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
There is no negotiation, yet, so be careful not to give the impression of conceding anything
February 11, 2026 - - Latest News -
Arrotex and Pfizer forge strategic pharmacy partnership for ENBREL in Australia
February 11, 2026 - - Latest News -
Amplia expands U.S. footprint as AMPLICITY pancreatic cancer trial gains momentum
February 11, 2026 - - Australian Biotech -
Canine osteoarthritis study offers compelling translational evidence for PPS
February 11, 2026 - - Australian Biotech -
CSL presses ahead with transformation as earnings slip and leadership changes
February 11, 2026 - - Latest News -
This might be the real once-in-a-generation opportunity achieve reform
February 11, 2026 - - Latest News -
CSL confirms leadership transition as Gordon Naylor steps in as interim CEO
February 10, 2026 - - Latest News